Kimberlee Drapkin

Kimberlee Cobleigh Drapkin currently serves as Independent Director at Acumen Pharmaceuticals, Inc. since 2022, Independent Non-Executive Director at Imugene Ltd. since 2023, Director at Lucy Therapeutics, Inc. since 2024, Independent Director at Climb Bio, Inc. starting 2025, Independent Director at LENZ Therapeutics, Inc. since 2023, and Member at Dana-Farber Cancer Institute, Inc. Former roles include President, CEO, CFO, Director & PAO at Graphite Bio, Inc. from 2023 to 2024; Independent Director at Proteostasis Therapeutics, Inc. from 2019 to 2020; Independent Director at Kineta, Inc. from 2023 to 2025; Independent Director at Yumanity Therapeutics, Inc. from 2019 to 2022; Director at Yumanity, Inc. from 2020 to 2022; Principal at Millennium Pharmaceuticals, Inc. from 1995 to 2005; Chief Financial Officer at EPIX Pharmaceuticals, Inc. from 2006 to 2009; Principal at PricewaterhouseCoopers LLP; Chief Financial Officer at Predix Pharmaceuticals, Inc., NinePoint Medical, Inc., Avila Therapeutics, Inc., Edimer Pharmaceuticals, Inc., Sesen Bio, Inc., Blueprint Medicines Corp., Warp Drive Bio, Inc., and Voyager Therapeutics, Inc.; Chief Financial Officer at Predix Pharmaceuticals Holdings, Inc. from 2005 to 2006; President, Chief Financial Officer & Treasurer at Jounce Therapeutics, Inc. in 2023; Chief Financial Officer & Owner at Kcd Financial Consultants LLC from 2012 to 2015.
Education includes undergraduate studies at Babson College.